Supporting female founder initiatives across the UK & Ireland

Find out more  
← Back to portfolio Porfolio / PredictImmune


Developer of pioneering prognostic tools

Company overview

Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).

Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.


Company information

Head office
  • Cambridge
  • Paul Kinnon
  • Andrew P Sandham
BGF office
Investment date
  • Jul 2019
Total BGF investment
  • £4 million